Spotlight on Hematology

Credits: 1.50 CME
Cracking the Code: Exploring Novel Frontline Treatments and Prospects for Maintenance Therapy in AML
Courtney DiNardo, MD
Integrity Continuing Education, Inc.

Cracking the Code: Exploring Novel Frontline Treatments and Prospects for Maintenance Therapy in AML

Start

Activity Details

Free CME
1.50 AMA PRA Category 1 Credit(s)
Released: February 25, 2021
Expires: February 25, 2022
90 minutes to complete

Accredited By

Target Audience

This educational initiative has been designed for hematologists, oncologists, and hematology/oncology fellows, attendings and trainees.

Learning Objectives

  • Correlate disease pathophysiology, cytogenetic, and molecular characteristics with targeted agents to individualize treatment of patients with acute myeloid leukemia (AML)
  • Evaluate recent changes to the standard treatment paradigm for newly diagnosed and relapsed/refractory patients with AML
  • Describe case scenarios in which maintenance therapy may become standard in the near future
  • Evaluate methods for measuring minimal residual disease (MRD) after complete remission to determine risk of relapse

Activity Description

This CME-certified interactive patient simulation on-demand activity will pose a series of questions to participating clinicians and provide immediate, personalized feedback based on individual responses. This activity will be bolstered by the inclusion of multimedia elements, including faculty video, key supporting slides, animations, interactive polling questions, text and graphics, and clinician support tools.

Statement of Educational Need

Once frustratingly slow, treatment advances in acute myeloid leukemia (AML) have been accelerating thanks to improved understanding of disease progression at the molecular level. Several new drug approvals have ended decades of stagnation in a field that had been notorious for lack of progress. Response rates to first and subsequent lines of therapy have been improving, especially among subsets of patients who carry actionable mutations. Nonetheless, relapse remains common. Novel therapies, consolidation chemotherapy, and/or hematopoietic stem cell transplant (HSCT) may prolong remissions, but relapse remains the primary obstacle to long-term survival. For this reason, maintenance therapy has had long-standing appeal and is finally emerging as a viable strategy that can be incorporated into clinical practice.

Faculty

Courtney DiNardo, MD
Associate Professor
Department of Leukemia
Division of Cancer Medicine
MD Anderson Cancer Center
Houston, Texas


Eytan M. Stein, MD
Assistant Professor
Director, Program for Drug Development in Leukemia
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Courtney DiNardo, MD
Consulting fees: AbbVie, Agios, BMS/Celgene, Daiichi-Sankyo, ImmuneOnc, Novartis, Takeda
Scientific Advisory Board with Stock Options: Notable Labs

Eytan Stein, MD
Consulting Fees: Agios, Amgen, Astellas, Celgene, Daiichi-Sankyo, Seattle Genetics, Syndax, and Syros
Ownership Interests: Auron Therapeutics

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of February 25, 2021 through February 25, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc.does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Astellas and Bristol Myers Squibb.

Activity Details

Free CME
1.50 AMA PRA Category 1 Credit(s)
Released: February 25, 2021
Expires: February 25, 2022
90 minutes to complete

Accredited By

Target Audience

This educational initiative has been designed for hematologists, oncologists, and hematology/oncology fellows, attendings and trainees.

Learning Objectives

  • Correlate disease pathophysiology, cytogenetic, and molecular characteristics with targeted agents to individualize treatment of patients with acute myeloid leukemia (AML)
  • Evaluate recent changes to the standard treatment paradigm for newly diagnosed and relapsed/refractory patients with AML
  • Describe case scenarios in which maintenance therapy may become standard in the near future
  • Evaluate methods for measuring minimal residual disease (MRD) after complete remission to determine risk of relapse

Activity Description

This CME-certified interactive patient simulation on-demand activity will pose a series of questions to participating clinicians and provide immediate, personalized feedback based on individual responses. This activity will be bolstered by the inclusion of multimedia elements, including faculty video, key supporting slides, animations, interactive polling questions, text and graphics, and clinician support tools.

Statement of Educational Need

Once frustratingly slow, treatment advances in acute myeloid leukemia (AML) have been accelerating thanks to improved understanding of disease progression at the molecular level. Several new drug approvals have ended decades of stagnation in a field that had been notorious for lack of progress. Response rates to first and subsequent lines of therapy have been improving, especially among subsets of patients who carry actionable mutations. Nonetheless, relapse remains common. Novel therapies, consolidation chemotherapy, and/or hematopoietic stem cell transplant (HSCT) may prolong remissions, but relapse remains the primary obstacle to long-term survival. For this reason, maintenance therapy has had long-standing appeal and is finally emerging as a viable strategy that can be incorporated into clinical practice.

Faculty

Courtney DiNardo, MD
Associate Professor
Department of Leukemia
Division of Cancer Medicine
MD Anderson Cancer Center
Houston, Texas


Eytan M. Stein, MD
Assistant Professor
Director, Program for Drug Development in Leukemia
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Courtney DiNardo, MD
Consulting fees: AbbVie, Agios, BMS/Celgene, Daiichi-Sankyo, ImmuneOnc, Novartis, Takeda
Scientific Advisory Board with Stock Options: Notable Labs

Eytan Stein, MD
Consulting Fees: Agios, Amgen, Astellas, Celgene, Daiichi-Sankyo, Seattle Genetics, Syndax, and Syros
Ownership Interests: Auron Therapeutics

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of February 25, 2021 through February 25, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc.does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Astellas and Bristol Myers Squibb.

Hematology Presentations

1.00 CME
The France Foundation
Conquer the Clot: Addressing VTE in Your Patients With Cancer

Conquer the Clot: Addressing VTE in Your Patients With Cancer

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: July 7, 2021
Expires: July 6, 2022
60 minutes to complete

Provided By

Target Audience

This activity is intended for hematologists/oncologists, medical oncologists, nurse practitioners (NPs), physician assistants (PAs), oncology pharmacists, and other health care professionals who are involved in the prevention and treatment of venous thromboembolism (VTE) in patients with cancer.

Learning Objectives

  • Identify appropriate patients for primary VTE prophylaxis through risk stratification assessments
  • Establish a plan for prevention of VTE in patients at elevated risk
  • Select appropriate therapy to treat VTE in patients with cancer, and select appropriate duration of treatment
  • Discuss with patients the risk and prevention of VTE

Activity Description

This 60-minute session provides education to the oncology team to support guideline-recommended care of patients with cancer, specifically related to: 1) appropriate VTE risk assessment and prophylaxis; 2) individualized VTE treatment; and 3) effective patient communication strategies related to VTE risk, prevention, and treatment. Throughout the session, the content is anchored in patient-care videos to engage the learner.

Statement of Educational Need

The prevention and treatment of cancer-associated thrombosis remains one of the most challenging areas of clinical medicine due to the intersection of cancer care and thrombosis management. Despite recent advances in patient risk stratification, prevention efforts, and treatment strategies, which have provided clinicians and patients with unprecedented management choices, individualized patient-centered management is needed to deliver optimal care.

Agenda

Know the Risk: Are Your Patients Protected? - Michael B. Streiff, MD, FACP
Critical Care: Preventing Cancer Associated Thrombosis in Your Patients - Alok A. Khorana, MD, FACP, FASCO
Conquer the Clot: Treating VTE in Your Patients With Cancer - Tzu-Fei Wang, MD, MPH

Faculty

Alok A. Khorana, MD, FACP, FASCO
Sondra and Stephen Hardis Chair in Oncology Research
Professor of Medicine, Cleveland Clinic Lerner College of Medicine
Taussig Cancer Institute and Case Comprehensive Cancer Center
Cleveland, Ohio


Michael B. Streiff, MD, FACP
Professor of Medicine and Pathology
Medical Director, Johns Hopkins Anticoagulation Service
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Chairman, NCCN Guidelines for Venous Thromboembolic Disease
Baltimore, Maryland


Tzu-Fei Wang, MD, MPH
Associate Professor, Division of Hematology, Department of Medicine
University of Ottawa at The Ottawa Hospital
Associate Scientist
Ottawa Hospital Research Institute
Ottawa, Canada

Faculty Disclosures

The faculty listed below report that they have relevant financial relationships to disclose:

  • Alok A. Khorana, MD, FACP, FASCO, serves as a consultant for Anthos, Bayer, BMS, Halozyme, Janssen, and Sanofi.
  • Michael B. Streiff, MD, FACP, serves as a consultant for Bayer, Bristol-Myers Squibb, Coagulo, Dispersol, Janssen, and Pfizer. He also receives research support from AHRQ, Janssen, NIH/NHLBI, Novo Nordisk, PCORI, Sanofi, and Tremeau.
  • Tzu-Fei Wang, MD, MPH, serves as a consultant for Servier. She also receives contract research support from Leo Pharma.

Accreditation Statement

This activity was planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation (TFF) and the International Society on Thrombosis and Haemostasis (ISTH). TFF is accredited by the ACCME to provide continuing medical education for physicians.

Physicians
The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Instructions for Receiving Credit

  1. Review the activity objectives and CME/CE information.
  2. Complete the CME/CE activity.
  3. Complete the online posttest. A score of at least 75% is required to complete this activity. The participant may take the test until successfully passed.
  4. Complete the CME/CE evaluation/attestation form. This form provides each participant the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  5. Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download

Statement of Commercial Support

This activity is supported by an educational grant from the BMS/Pfizer Alliance.

Disclaimer Statement/Disclosure of Unlabeled Use

TFF and the ISTH require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and the ISTH do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: July 7, 2021
Expires: July 6, 2022
60 minutes to complete

Provided By

Target Audience

This activity is intended for hematologists/oncologists, medical oncologists, nurse practitioners (NPs), physician assistants (PAs), oncology pharmacists, and other health care professionals who are involved in the prevention and treatment of venous thromboembolism (VTE) in patients with cancer.

Learning Objectives

  • Identify appropriate patients for primary VTE prophylaxis through risk stratification assessments
  • Establish a plan for prevention of VTE in patients at elevated risk
  • Select appropriate therapy to treat VTE in patients with cancer, and select appropriate duration of treatment
  • Discuss with patients the risk and prevention of VTE

Activity Description

This 60-minute session provides education to the oncology team to support guideline-recommended care of patients with cancer, specifically related to: 1) appropriate VTE risk assessment and prophylaxis; 2) individualized VTE treatment; and 3) effective patient communication strategies related to VTE risk, prevention, and treatment. Throughout the session, the content is anchored in patient-care videos to engage the learner.

Statement of Educational Need

The prevention and treatment of cancer-associated thrombosis remains one of the most challenging areas of clinical medicine due to the intersection of cancer care and thrombosis management. Despite recent advances in patient risk stratification, prevention efforts, and treatment strategies, which have provided clinicians and patients with unprecedented management choices, individualized patient-centered management is needed to deliver optimal care.

Agenda

Know the Risk: Are Your Patients Protected? - Michael B. Streiff, MD, FACP
Critical Care: Preventing Cancer Associated Thrombosis in Your Patients - Alok A. Khorana, MD, FACP, FASCO
Conquer the Clot: Treating VTE in Your Patients With Cancer - Tzu-Fei Wang, MD, MPH

Faculty

Alok A. Khorana, MD, FACP, FASCO
Sondra and Stephen Hardis Chair in Oncology Research
Professor of Medicine, Cleveland Clinic Lerner College of Medicine
Taussig Cancer Institute and Case Comprehensive Cancer Center
Cleveland, Ohio


Michael B. Streiff, MD, FACP
Professor of Medicine and Pathology
Medical Director, Johns Hopkins Anticoagulation Service
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Chairman, NCCN Guidelines for Venous Thromboembolic Disease
Baltimore, Maryland


Tzu-Fei Wang, MD, MPH
Associate Professor, Division of Hematology, Department of Medicine
University of Ottawa at The Ottawa Hospital
Associate Scientist
Ottawa Hospital Research Institute
Ottawa, Canada

Faculty Disclosures

The faculty listed below report that they have relevant financial relationships to disclose:

  • Alok A. Khorana, MD, FACP, FASCO, serves as a consultant for Anthos, Bayer, BMS, Halozyme, Janssen, and Sanofi.
  • Michael B. Streiff, MD, FACP, serves as a consultant for Bayer, Bristol-Myers Squibb, Coagulo, Dispersol, Janssen, and Pfizer. He also receives research support from AHRQ, Janssen, NIH/NHLBI, Novo Nordisk, PCORI, Sanofi, and Tremeau.
  • Tzu-Fei Wang, MD, MPH, serves as a consultant for Servier. She also receives contract research support from Leo Pharma.

Accreditation Statement

This activity was planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation (TFF) and the International Society on Thrombosis and Haemostasis (ISTH). TFF is accredited by the ACCME to provide continuing medical education for physicians.

Physicians
The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Instructions for Receiving Credit

  1. Review the activity objectives and CME/CE information.
  2. Complete the CME/CE activity.
  3. Complete the online posttest. A score of at least 75% is required to complete this activity. The participant may take the test until successfully passed.
  4. Complete the CME/CE evaluation/attestation form. This form provides each participant the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  5. Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download

Statement of Commercial Support

This activity is supported by an educational grant from the BMS/Pfizer Alliance.

Disclaimer Statement/Disclosure of Unlabeled Use

TFF and the ISTH require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and the ISTH do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

0.75 CME / MOC / CNE
RMEI Medical Education, LLC
Changing Perspectives—Fine Tuning Treatment for the Relapsed Refractory Patient with Chronic Myeloid Leukemia

Changing Perspectives—Fine Tuning Treatment for the Relapsed Refractory Patient with Chronic Myeloid Leukemia

Start

Activity Details

Free CME/MOC/CNE
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Points
0.75 ANCC Contact Hours
Released: June 15, 2021
Expires: June 14, 2022
45 minutes to complete

Accredited By

Provided by RMEI Medical Education, LLC

Target Audience

This activity is intended for medical oncologists, hematologists, NPs, PAs, nurses, and other HCPs engaged in the care of patients with chronic myeloid leukemia (CML).

Learning Objectives

After completing this activity, the clinician should be able to:

  • Employ key data on tyrosine kinase inhibitors (TKIs) when treating and monitoring patients with relapsed or refractory CML
  • Select appropriate therapy for patients with CML refractory to 2nd generation agents
  • Integrate strategies to monitor and manage potential adverse effects, such as cardiotoxicity, that may result in cross-intolerance to TKIs in patients with CML

Activity Description

This Clinical Convergence™ activity addresses new developments in the treatment of relapsed/refractory CML with a focus on appropriate therapeutic decision making and monitoring in the second- and third-line setting. The program features a clinical case vignette to engage the learner and facilitate acquisition and integration of new skills and behaviors, as well as a patient encounter to provide unique perspectives on aspects of treatment selection, adherence, monitoring requirements, and adverse event management. A non-certified practice aid is included as a resource for provider-patient discussions on potential side effects.

Course Director

Jorge Cortes, MD
Director, Georgia Cancer Center
Cecil F. Whitaker Jr., GRA Eminent Scholar Chair in Cancer
Augusta, GA

Faculty

Mahran Shoukier, MD
Hematology/Oncology Fellow
Section of Hematology/Oncology, Department of Medicine
Georgia Cancer Center at Augusta University
Augusta, GA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Jorge Cortes, MD, has affiliations with Novartis, Pfizer, Sun Pharmaceuticals, Takeda (Consultant and Grant Research Support).

Mahran Shoukier, MD, has no relevant financial relationship(s) with ineligible companies to disclose.

Patient
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planner, Sara Fagerlie, PhD, CHCP, has an affiliation with Adaptive Biotechnologies. All other RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour(s).

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must:

  • Review and successfully complete the activity
  • Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.

No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/MOC/CNE
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Points
0.75 ANCC Contact Hours
Released: June 15, 2021
Expires: June 14, 2022
45 minutes to complete

Accredited By

Provided by RMEI Medical Education, LLC

Target Audience

This activity is intended for medical oncologists, hematologists, NPs, PAs, nurses, and other HCPs engaged in the care of patients with chronic myeloid leukemia (CML).

Learning Objectives

After completing this activity, the clinician should be able to:

  • Employ key data on tyrosine kinase inhibitors (TKIs) when treating and monitoring patients with relapsed or refractory CML
  • Select appropriate therapy for patients with CML refractory to 2nd generation agents
  • Integrate strategies to monitor and manage potential adverse effects, such as cardiotoxicity, that may result in cross-intolerance to TKIs in patients with CML

Activity Description

This Clinical Convergence™ activity addresses new developments in the treatment of relapsed/refractory CML with a focus on appropriate therapeutic decision making and monitoring in the second- and third-line setting. The program features a clinical case vignette to engage the learner and facilitate acquisition and integration of new skills and behaviors, as well as a patient encounter to provide unique perspectives on aspects of treatment selection, adherence, monitoring requirements, and adverse event management. A non-certified practice aid is included as a resource for provider-patient discussions on potential side effects.

Course Director

Jorge Cortes, MD
Director, Georgia Cancer Center
Cecil F. Whitaker Jr., GRA Eminent Scholar Chair in Cancer
Augusta, GA

Faculty

Mahran Shoukier, MD
Hematology/Oncology Fellow
Section of Hematology/Oncology, Department of Medicine
Georgia Cancer Center at Augusta University
Augusta, GA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Jorge Cortes, MD, has affiliations with Novartis, Pfizer, Sun Pharmaceuticals, Takeda (Consultant and Grant Research Support).

Mahran Shoukier, MD, has no relevant financial relationship(s) with ineligible companies to disclose.

Patient
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planner, Sara Fagerlie, PhD, CHCP, has an affiliation with Adaptive Biotechnologies. All other RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour(s).

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must:

  • Review and successfully complete the activity
  • Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.

No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

1.00 CME / CNE / CPE
Rush University Medical Center
Advances in CAR T-Cell Therapies: Optimizing Outcomes and Implementation in Hematologic Malignancies

Advances in CAR T-Cell Therapies: Optimizing Outcomes and Implementation in Hematologic Malignancies

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: June 9, 2021
Expires: June 8, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with hematologic malignancies.

Learning Objectives

After completing this program, participants should be able to:

  1. Assess the latest developments in CAR T-cell therapies for relapsed/refractory hematologic malignancies, including ongoing clinical trials.
  2. Identify adverse effects associated with CAR T-cell therapies in hematologic malignancies and describe effective approaches to appropriately manage these effects.
  3. Outline factors that interfere with the application of CAR T-cell therapies and formulate strategies to overcome these barriers.

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of hematologic malignancies. This educational activity will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

With the recent advances in CAR T-cell therapies for hematologic malignancies, the use of approved and investigational agents is anticipated to expand over the coming years. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the application of CAR T-cell therapy, ongoing clinical trials of CAR T-cell therapies, appropriate management of associated adverse effects, and best practices to overcome barriers associated with implementation of this treatment approach.

Faculty

Caron Jacobson, MD
Assistant Professor
Division of Medical Oncology
Department of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Conflict of Interest Policy/Disclosure Statement

Dr. Jacobson has consulted for:
Kite/Gilead, Novartis, BMS/Celgene, Nkarta, Lonza, bluebird bio, Precision Biosciences, Abbvie, Ipsen

Dr. Jacobson has research grants from
Pfizer, Kite Pharma

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from BMS, Gilead, Janssen Biotech, Inc., and Kite Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: June 9, 2021
Expires: June 8, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with hematologic malignancies.

Learning Objectives

After completing this program, participants should be able to:

  1. Assess the latest developments in CAR T-cell therapies for relapsed/refractory hematologic malignancies, including ongoing clinical trials.
  2. Identify adverse effects associated with CAR T-cell therapies in hematologic malignancies and describe effective approaches to appropriately manage these effects.
  3. Outline factors that interfere with the application of CAR T-cell therapies and formulate strategies to overcome these barriers.

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of hematologic malignancies. This educational activity will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

With the recent advances in CAR T-cell therapies for hematologic malignancies, the use of approved and investigational agents is anticipated to expand over the coming years. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the application of CAR T-cell therapy, ongoing clinical trials of CAR T-cell therapies, appropriate management of associated adverse effects, and best practices to overcome barriers associated with implementation of this treatment approach.

Faculty

Caron Jacobson, MD
Assistant Professor
Division of Medical Oncology
Department of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Conflict of Interest Policy/Disclosure Statement

Dr. Jacobson has consulted for:
Kite/Gilead, Novartis, BMS/Celgene, Nkarta, Lonza, bluebird bio, Precision Biosciences, Abbvie, Ipsen

Dr. Jacobson has research grants from
Pfizer, Kite Pharma

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from BMS, Gilead, Janssen Biotech, Inc., and Kite Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

0.25 CME / MOC
American Society of Hematology
The Changing Therapeutic Landscape of Sickle Cell Disease

The Changing Therapeutic Landscape of Sickle Cell Disease

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC Part II points
Released: June 2, 2021
Expires: March 31, 2022
15 minutes to complete

Accredited By

Target Audience

This activity is intended for administrative and clinical professionals (hematologists, general internists, advanced practice professionals, social workers) seeking to develop adult comprehensive care programs at their institutions.

Learning Objective

Upon completion of this course, the participants should be able to:

  • Outline approaches to optimal clinical care for patients with Sickle Cell Disease (SCD)

Activity Description

There are many new therapies for sickle cell disease. Understanding how they work and where they work is crucial to managing patients. Dr. Julie Kanter explains the latest approved therapies and invites you to demonstrate your knowledge through interactive games.

Agenda

  • Pathophysiology of Sickle Cell Disease
  • Clinical manifestations and complications of SCD
  • Novel therapies in SCD
  • Curative therapies

Activity Faculty

Julie Kanter, MD
SCD Centers Workshop Co-Director
Associate Professor, Division of Hematology & Oncology
The University of Alabama at Birmingham
Birmingham, Alabama

Steering Committee Faculty

Payal Desai, MD
Director of Sickle Cell Research
Co-Director of Sickle Cell Program
The Ohio State University
Columbus, Ohio

Sophie Lanzkron, MD
SCD Centers Workshop Co-Director
Associate Professor of Medicine and Oncology, Division of Hematology
Director, Sickle Cell Center for Adults
Johns Hopkins Medicine
Baltimore, Maryland

Wally R. Smith, MD
SCD Centers Workshop Co-Director
Florence Neal Cooper Smith Professor of Sickle Cell Disease
Vice Chairman for Research, Division of General Internal Medicine
Virginia Commonwealth University
Richmond, Virginia

Conflict of Interest Policy/Disclosure Statement

The France Foundation participated in the development of this activity in collaboration with The American Society of Hematology. In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and the American Society of Hematology (ASH) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ASH resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and ASH seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASH are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

The following staff at TFF report that they have relevant financial relationships to disclose:

  • Patrick Harty, PhD, reports that his spouse is employed by Pfizer, Inc. and they hold stock in Pfizer, Inc.

The planners, reviewers, editors, staff, CME committee, or other members at ASH who control content have no relevant financial relationships to disclose.

The faculty listed below report that they have no relevant financial relationships to disclose:

  • Dr. Desai does consulting for Accel Pharma and serves on the speakers bureau for Novartis. She does contract research for Global Blood Therapeutics and UPMC. Dr. Desai is also writing a publication for Pfizer, Inc.
  • Dr. Kanter does consulting for Axcella Health, Gerson Lehrman Group, Graphite, Guidepoint Global, Imara, Novartis, and Wells Fargo. She also serves on advisory boards for Acel Rx, Agios, Astrazeneca, Beam Therapeutics, Forma Therapeutics, Novartis, Novo Nordisk, Sanofi, and Sancillo.
  • Dr. Lanzkron does consulting for bluebird bio, Novo Nordisk, and Pfizer, Inc. She is a site primary investigator for contract research for Imara, Shire, and Novartis. Dr. Lanzkron also owns stock in Pfizer, Inc. and Teva Pharmaceuticals.
  • Dr. Smith does consulting for GBT, GMI, Novartis, and Pfizer, Inc. He also does contract research for GBT, Imara, Novartis, and Shire.

Accreditation Statement

The American Society of Hematology (ASH) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Physicians
ASH designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The America Society of Hematology, an ACCME accredited provider.

Method of Participation/How to Receive Credit

  1. There are no fees for participating in and receiving credit for this activity.
  2. Review the activity objectives and CME/CE information.
  3. Complete the CME/CE activity.
  4. Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
  5. Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
  6. Credit documentation/reporting:

Statement of Commercial Support

This activity is supported by educational grants from bluebird bio, Forma Therapeutics, Global Blood Therapeutics, and Novartis.

Disclaimer Statement/Disclosure of Unlabeled Use

TFF and ASH require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ASH do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

The France Foundation and the American Society of Hematology present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. TFF, ASH, and the commercial supporter(s) assume no liability for the information herein.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC Part II points
Released: June 2, 2021
Expires: March 31, 2022
15 minutes to complete

Accredited By

Target Audience

This activity is intended for administrative and clinical professionals (hematologists, general internists, advanced practice professionals, social workers) seeking to develop adult comprehensive care programs at their institutions.

Learning Objective

Upon completion of this course, the participants should be able to:

  • Outline approaches to optimal clinical care for patients with Sickle Cell Disease (SCD)

Activity Description

There are many new therapies for sickle cell disease. Understanding how they work and where they work is crucial to managing patients. Dr. Julie Kanter explains the latest approved therapies and invites you to demonstrate your knowledge through interactive games.

Agenda

  • Pathophysiology of Sickle Cell Disease
  • Clinical manifestations and complications of SCD
  • Novel therapies in SCD
  • Curative therapies

Activity Faculty

Julie Kanter, MD
SCD Centers Workshop Co-Director
Associate Professor, Division of Hematology & Oncology
The University of Alabama at Birmingham
Birmingham, Alabama

Steering Committee Faculty

Payal Desai, MD
Director of Sickle Cell Research
Co-Director of Sickle Cell Program
The Ohio State University
Columbus, Ohio

Sophie Lanzkron, MD
SCD Centers Workshop Co-Director
Associate Professor of Medicine and Oncology, Division of Hematology
Director, Sickle Cell Center for Adults
Johns Hopkins Medicine
Baltimore, Maryland

Wally R. Smith, MD
SCD Centers Workshop Co-Director
Florence Neal Cooper Smith Professor of Sickle Cell Disease
Vice Chairman for Research, Division of General Internal Medicine
Virginia Commonwealth University
Richmond, Virginia

Conflict of Interest Policy/Disclosure Statement

The France Foundation participated in the development of this activity in collaboration with The American Society of Hematology. In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and the American Society of Hematology (ASH) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ASH resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and ASH seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASH are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

The following staff at TFF report that they have relevant financial relationships to disclose:

  • Patrick Harty, PhD, reports that his spouse is employed by Pfizer, Inc. and they hold stock in Pfizer, Inc.

The planners, reviewers, editors, staff, CME committee, or other members at ASH who control content have no relevant financial relationships to disclose.

The faculty listed below report that they have no relevant financial relationships to disclose:

  • Dr. Desai does consulting for Accel Pharma and serves on the speakers bureau for Novartis. She does contract research for Global Blood Therapeutics and UPMC. Dr. Desai is also writing a publication for Pfizer, Inc.
  • Dr. Kanter does consulting for Axcella Health, Gerson Lehrman Group, Graphite, Guidepoint Global, Imara, Novartis, and Wells Fargo. She also serves on advisory boards for Acel Rx, Agios, Astrazeneca, Beam Therapeutics, Forma Therapeutics, Novartis, Novo Nordisk, Sanofi, and Sancillo.
  • Dr. Lanzkron does consulting for bluebird bio, Novo Nordisk, and Pfizer, Inc. She is a site primary investigator for contract research for Imara, Shire, and Novartis. Dr. Lanzkron also owns stock in Pfizer, Inc. and Teva Pharmaceuticals.
  • Dr. Smith does consulting for GBT, GMI, Novartis, and Pfizer, Inc. He also does contract research for GBT, Imara, Novartis, and Shire.

Accreditation Statement

The American Society of Hematology (ASH) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Physicians
ASH designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The America Society of Hematology, an ACCME accredited provider.

Method of Participation/How to Receive Credit

  1. There are no fees for participating in and receiving credit for this activity.
  2. Review the activity objectives and CME/CE information.
  3. Complete the CME/CE activity.
  4. Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
  5. Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
  6. Credit documentation/reporting:

Statement of Commercial Support

This activity is supported by educational grants from bluebird bio, Forma Therapeutics, Global Blood Therapeutics, and Novartis.

Disclaimer Statement/Disclosure of Unlabeled Use

TFF and ASH require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ASH do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

The France Foundation and the American Society of Hematology present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. TFF, ASH, and the commercial supporter(s) assume no liability for the information herein.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

1.00 CME / CNE / CPE
Rush University Medical Center
Expert Perspectives on Treating High-Risk and Relapsed/Refractory Acute Myeloid Leukemia

Expert Perspectives on Treating High-Risk and Relapsed/Refractory Acute Myeloid Leukemia

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: April 30, 2021
Expires: April 29, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with acute myeloid leukemia.

Learning Objectives

After completing this program, participants should be able to:

  1. Summarize recommendations for molecular and cytogenic testing of patients with AML and how these results can be used to inform treatment decisions.
  2. Formulate informed treatment plans for patients with high-risk or relapsed/refractory AML, taking into consideration the latest clinical evidence regarding the safety and efficacy of recently approved therapies.
  3. Assess late-phase clinical trial data on investigational therapies and novel combination approaches within the context of existing AML treatment paradigms.

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of acute myeloid leukemia.This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

High-risk and relapsed/refractory AML represent significant clinical challenges. Within the past several years, eight novel agents have been approved for the treatment of AML, providing hope for improved outcomes in the coming years. With the wide variety of agents under development for the treatment of high-risk and relapsed/refractory AML, the use of recently approved and investigational agents is anticipated to continue to expand over the next few years. To continue to provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the utility of agents that could significantly impact clinical practice.

Faculty

Eytan M. Stein, MD
Director, Program for Drug Development in Leukemia
Assistant Professor
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

Dr. Stein has consulted for:
Syndax, Syros, Novartis, Astellas, Daiichi, Gilead, Abbvie, Genentech, Janssen, BMS, Celgene, Agios, Blueprint, Neoleukin, PinotBio

Dr. Stein has research grants from:
Bayer, Syndax, Novartis, Biotheryx, Gilead, Agios

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by educational grants from AbbVie Inc., Agios Pharmaceuticals, Inc., and Daiichi Sankyo, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: April 30, 2021
Expires: April 29, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with acute myeloid leukemia.

Learning Objectives

After completing this program, participants should be able to:

  1. Summarize recommendations for molecular and cytogenic testing of patients with AML and how these results can be used to inform treatment decisions.
  2. Formulate informed treatment plans for patients with high-risk or relapsed/refractory AML, taking into consideration the latest clinical evidence regarding the safety and efficacy of recently approved therapies.
  3. Assess late-phase clinical trial data on investigational therapies and novel combination approaches within the context of existing AML treatment paradigms.

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of acute myeloid leukemia.This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

High-risk and relapsed/refractory AML represent significant clinical challenges. Within the past several years, eight novel agents have been approved for the treatment of AML, providing hope for improved outcomes in the coming years. With the wide variety of agents under development for the treatment of high-risk and relapsed/refractory AML, the use of recently approved and investigational agents is anticipated to continue to expand over the next few years. To continue to provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the utility of agents that could significantly impact clinical practice.

Faculty

Eytan M. Stein, MD
Director, Program for Drug Development in Leukemia
Assistant Professor
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

Dr. Stein has consulted for:
Syndax, Syros, Novartis, Astellas, Daiichi, Gilead, Abbvie, Genentech, Janssen, BMS, Celgene, Agios, Blueprint, Neoleukin, PinotBio

Dr. Stein has research grants from:
Bayer, Syndax, Novartis, Biotheryx, Gilead, Agios

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by educational grants from AbbVie Inc., Agios Pharmaceuticals, Inc., and Daiichi Sankyo, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

1.00 CME / CNE / CPE
Rush University Medical Center
Clinical Strategies to Optimize Outcomes Across the Disease Spectrum in Multiple Myeloma

Clinical Strategies to Optimize Outcomes Across the Disease Spectrum in Multiple Myeloma

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: March 9, 2021
Expires: March 8, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with multiple myeloma.

Learning Objectives

After completing this program, participants should be able to:

  1. Develop individualized treatment plans for MM patients in the VHA, DoD and MHS settings based on risk and cytogenetic and genomic data
  2. Recognize the disease-, treatment-, and patient-related factors that affect risk stratification and the selection and sequencing of novel drug combination therapies across the disease spectrum for multiple myeloma
  3. Evaluate emerging clinical data and describe risk/benefit of current and evolving treatment approaches across the disease spectrum of multiple myeloma

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of multiple myeloma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

With a significant number of new drug approvals and label-updates since 2015, the multiple myeloma (MM) treatment landscape is rapidly evolving. New therapeutic options have resulted in improved clinical outcomes for patients with multiple myeloma and have transformed this disease into a chronic condition that can be managed over a longer course of years. As an increasing number of clinical trials are progressing, treatments for multiple myeloma will continue to improve and current treatment algorithms will continue to evolve.

The goal of this activity is to provide clinicians with insights into the decision-making strategies necessary to make best use of available therapeutic options in an individual patient and how and when treatments can be combined to improve control of the underlying disease.

Faculty

Jeffrey V. Matous, MD
Medical Director, Colorado Blood Cancer Institute
Clinical Professor of Medicine
University of Colorado Health Sciences Center
Denver, CO


Conflict of Interest Policy/Disclosure Statement

Research Grant: Pharmacyclics
Consultant: Pharmacyclics

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from Bristol Myers Squibb and Karyopharm Therapeutics, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: March 9, 2021
Expires: March 8, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with multiple myeloma.

Learning Objectives

After completing this program, participants should be able to:

  1. Develop individualized treatment plans for MM patients in the VHA, DoD and MHS settings based on risk and cytogenetic and genomic data
  2. Recognize the disease-, treatment-, and patient-related factors that affect risk stratification and the selection and sequencing of novel drug combination therapies across the disease spectrum for multiple myeloma
  3. Evaluate emerging clinical data and describe risk/benefit of current and evolving treatment approaches across the disease spectrum of multiple myeloma

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of multiple myeloma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

With a significant number of new drug approvals and label-updates since 2015, the multiple myeloma (MM) treatment landscape is rapidly evolving. New therapeutic options have resulted in improved clinical outcomes for patients with multiple myeloma and have transformed this disease into a chronic condition that can be managed over a longer course of years. As an increasing number of clinical trials are progressing, treatments for multiple myeloma will continue to improve and current treatment algorithms will continue to evolve.

The goal of this activity is to provide clinicians with insights into the decision-making strategies necessary to make best use of available therapeutic options in an individual patient and how and when treatments can be combined to improve control of the underlying disease.

Faculty

Jeffrey V. Matous, MD
Medical Director, Colorado Blood Cancer Institute
Clinical Professor of Medicine
University of Colorado Health Sciences Center
Denver, CO


Conflict of Interest Policy/Disclosure Statement

Research Grant: Pharmacyclics
Consultant: Pharmacyclics

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from Bristol Myers Squibb and Karyopharm Therapeutics, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

0.50 CME
Vindico
Cytomegalovirus in the Transplantation Setting: Assessing the Evidence in Real-world Applications - A Game On! Challenge

Cytomegalovirus in the Transplantation Setting: Assessing the Evidence in Real-world Applications - A Game On! Challenge

Start

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit(s)
Released: March 2, 2021
Expires: March 1, 2022
30 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists and other health care professionals involved in the management of patients with cytomegalovirus.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Incorporate recent evidence into practice regarding the use of prophylactic and preemptive measures to prevent cytomegalovirus (CMV) disease in transplant recipients.
  • Differentiate conventional versus newer antiviral therapies in terms of safety and efficacy, ability to reduce CMV reactivation, and improvement of survival in transplant recipients.
  • Evaluate the optimal duration of prophylactic or preemptive treatment in patients at risk for CMV reactivation.

Activity Description

Cytomegalovirus (CMV) infection after solid organ and hematopoietic stem cell transplantation is one of the most critical infectious complications related to host immune recovery. Management of the virus is categorized into prophylactic, preemptive, and targeted treatment. Conventional anti-CMV therapies are associated with suboptimal efficacy, toxicity, and resistance. Newer antivirals may provide effective prevention as well as treatment of CMV disease without the safety concerns and drug resistance. In this continuing medical education activity, expert clinicians will discuss the latest on diagnosing and managing patients with CMV infection in the transplantation setting.

Faculty

Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Chief Infection Control Officer
Department of ID/IC/EH
University of Texas MD Anderson Cancer Center
Houston, TX

Disclosure:
Consulting Fee: Ansun BioPharma, Chimerix, Cidara, Janssen, Merck, Oxford Immunotec, ReViral, Takeda
Speakers Bureau: Merck
Contracted Research: AiCuris, Ansun BioPharma, Janssen, Karius, Merck, Takeda, Viracor

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, March 2, 2021 to March 1, 2022.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit(s)
Released: March 2, 2021
Expires: March 1, 2022
30 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists and other health care professionals involved in the management of patients with cytomegalovirus.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Incorporate recent evidence into practice regarding the use of prophylactic and preemptive measures to prevent cytomegalovirus (CMV) disease in transplant recipients.
  • Differentiate conventional versus newer antiviral therapies in terms of safety and efficacy, ability to reduce CMV reactivation, and improvement of survival in transplant recipients.
  • Evaluate the optimal duration of prophylactic or preemptive treatment in patients at risk for CMV reactivation.

Activity Description

Cytomegalovirus (CMV) infection after solid organ and hematopoietic stem cell transplantation is one of the most critical infectious complications related to host immune recovery. Management of the virus is categorized into prophylactic, preemptive, and targeted treatment. Conventional anti-CMV therapies are associated with suboptimal efficacy, toxicity, and resistance. Newer antivirals may provide effective prevention as well as treatment of CMV disease without the safety concerns and drug resistance. In this continuing medical education activity, expert clinicians will discuss the latest on diagnosing and managing patients with CMV infection in the transplantation setting.

Faculty

Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Chief Infection Control Officer
Department of ID/IC/EH
University of Texas MD Anderson Cancer Center
Houston, TX

Disclosure:
Consulting Fee: Ansun BioPharma, Chimerix, Cidara, Janssen, Merck, Oxford Immunotec, ReViral, Takeda
Speakers Bureau: Merck
Contracted Research: AiCuris, Ansun BioPharma, Janssen, Karius, Merck, Takeda, Viracor

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, March 2, 2021 to March 1, 2022.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.50 CME
Integrity Continuing Education, Inc.
Cracking the Code: Exploring Novel Frontline Treatments and Prospects for Maintenance Therapy in AML

Cracking the Code: Exploring Novel Frontline Treatments and Prospects for Maintenance Therapy in AML

Start

Activity Details

Free CME
1.50 AMA PRA Category 1 Credit(s)
Released: February 25, 2021
Expires: February 25, 2022
90 minutes to complete

Accredited By

Target Audience

This educational initiative has been designed for hematologists, oncologists, and hematology/oncology fellows, attendings and trainees.

Learning Objectives

  • Correlate disease pathophysiology, cytogenetic, and molecular characteristics with targeted agents to individualize treatment of patients with acute myeloid leukemia (AML)
  • Evaluate recent changes to the standard treatment paradigm for newly diagnosed and relapsed/refractory patients with AML
  • Describe case scenarios in which maintenance therapy may become standard in the near future
  • Evaluate methods for measuring minimal residual disease (MRD) after complete remission to determine risk of relapse

Activity Description

This CME-certified interactive patient simulation on-demand activity will pose a series of questions to participating clinicians and provide immediate, personalized feedback based on individual responses. This activity will be bolstered by the inclusion of multimedia elements, including faculty video, key supporting slides, animations, interactive polling questions, text and graphics, and clinician support tools.

Statement of Educational Need

Once frustratingly slow, treatment advances in acute myeloid leukemia (AML) have been accelerating thanks to improved understanding of disease progression at the molecular level. Several new drug approvals have ended decades of stagnation in a field that had been notorious for lack of progress. Response rates to first and subsequent lines of therapy have been improving, especially among subsets of patients who carry actionable mutations. Nonetheless, relapse remains common. Novel therapies, consolidation chemotherapy, and/or hematopoietic stem cell transplant (HSCT) may prolong remissions, but relapse remains the primary obstacle to long-term survival. For this reason, maintenance therapy has had long-standing appeal and is finally emerging as a viable strategy that can be incorporated into clinical practice.

Faculty

Courtney DiNardo, MD
Associate Professor
Department of Leukemia
Division of Cancer Medicine
MD Anderson Cancer Center
Houston, Texas


Eytan M. Stein, MD
Assistant Professor
Director, Program for Drug Development in Leukemia
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Courtney DiNardo, MD
Consulting fees: AbbVie, Agios, BMS/Celgene, Daiichi-Sankyo, ImmuneOnc, Novartis, Takeda
Scientific Advisory Board with Stock Options: Notable Labs

Eytan Stein, MD
Consulting Fees: Agios, Amgen, Astellas, Celgene, Daiichi-Sankyo, Seattle Genetics, Syndax, and Syros
Ownership Interests: Auron Therapeutics

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of February 25, 2021 through February 25, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc.does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Astellas and Bristol Myers Squibb.

Activity Details

Free CME
1.50 AMA PRA Category 1 Credit(s)
Released: February 25, 2021
Expires: February 25, 2022
90 minutes to complete

Accredited By

Target Audience

This educational initiative has been designed for hematologists, oncologists, and hematology/oncology fellows, attendings and trainees.

Learning Objectives

  • Correlate disease pathophysiology, cytogenetic, and molecular characteristics with targeted agents to individualize treatment of patients with acute myeloid leukemia (AML)
  • Evaluate recent changes to the standard treatment paradigm for newly diagnosed and relapsed/refractory patients with AML
  • Describe case scenarios in which maintenance therapy may become standard in the near future
  • Evaluate methods for measuring minimal residual disease (MRD) after complete remission to determine risk of relapse

Activity Description

This CME-certified interactive patient simulation on-demand activity will pose a series of questions to participating clinicians and provide immediate, personalized feedback based on individual responses. This activity will be bolstered by the inclusion of multimedia elements, including faculty video, key supporting slides, animations, interactive polling questions, text and graphics, and clinician support tools.

Statement of Educational Need

Once frustratingly slow, treatment advances in acute myeloid leukemia (AML) have been accelerating thanks to improved understanding of disease progression at the molecular level. Several new drug approvals have ended decades of stagnation in a field that had been notorious for lack of progress. Response rates to first and subsequent lines of therapy have been improving, especially among subsets of patients who carry actionable mutations. Nonetheless, relapse remains common. Novel therapies, consolidation chemotherapy, and/or hematopoietic stem cell transplant (HSCT) may prolong remissions, but relapse remains the primary obstacle to long-term survival. For this reason, maintenance therapy has had long-standing appeal and is finally emerging as a viable strategy that can be incorporated into clinical practice.

Faculty

Courtney DiNardo, MD
Associate Professor
Department of Leukemia
Division of Cancer Medicine
MD Anderson Cancer Center
Houston, Texas


Eytan M. Stein, MD
Assistant Professor
Director, Program for Drug Development in Leukemia
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Courtney DiNardo, MD
Consulting fees: AbbVie, Agios, BMS/Celgene, Daiichi-Sankyo, ImmuneOnc, Novartis, Takeda
Scientific Advisory Board with Stock Options: Notable Labs

Eytan Stein, MD
Consulting Fees: Agios, Amgen, Astellas, Celgene, Daiichi-Sankyo, Seattle Genetics, Syndax, and Syros
Ownership Interests: Auron Therapeutics

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of February 25, 2021 through February 25, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc.does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Astellas and Bristol Myers Squibb.

0.25 CME
University of Nebraska Medical Center
Experts Debate Optimal Approaches to the Treatment of Multiple Myeloma CME

Experts Debate Optimal Approaches to the Treatment of Multiple Myeloma CME

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: February 1, 2021
Expires: February 1, 2022
15 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with hematologic malignancies.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Evaluate clinical trial results of frontline treatment options that are available for the treatment of patients with newly diagnosed MM
  • Review maintenance therapy strategies for patients with MM that are eligible to receive this type of therapy
  • Assess treatment approaches and sequencing of therapy for patients with relapsed and/or refractory MM
  • Optimize approaches to manage treatment-related adverse events that may occur during the treatment of patients with MM
  • Discuss clinical trials results that are investigating emerging novel agents in patients with MM

Activity Description

Major advances in the diagnosis and treatment of multiple myeloma (MM) have occurred in the past decade. In the future, studies will continue to address issues such as optimal sequencing of therapies, the incorporation of novel agents as they are approved into existing regimens, the role of MRD, optimal treatment of high-risk disease, and early interventions as a potential cure. This educational activity will provide the most up-to-date information to clinicians treating patients with MM, strategies to evaluate best practices and emerging clinical data, and expert insights on how to apply them safely and effectively to your patients.

Statement of Educational Need

Given the recent approval of various therapies for the treatment of patients with multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents, it is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage AEs. Thus, we propose to facilitate evaluation of emerging scientific and clinical data, and appropriate use of current and emerging therapies, by clinicians who treat patients with MM.

Faculty

Sagar Lonial, MD, FACP
Chief Medical Officer
Winship Cancer Institute of Emory University
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Emory University School of Medicine
Atlanta, Georgia

Pieter Sonneveld, MD, PhD
Professor of Hematology
Erasmus MC Cancer Institute/University Medical Center
Rotterdam, The Netherlands

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Conflict of Interest Policy/Disclosure Statement

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Faculty
Sagar Lonial, MD, FACP
Consulting Fees: Amgen Inc., Bristol Myers Squibb Company, Celgene Corporation, GlaxoSmithKline LLC, Janssen Oncology, Karyopharm Therapeutics, Merck & Co., Novartis

Pieter Sonneveld, MD, PhD
Employment: Hematology, Erasmus MC Cancer Institute, Rotterdam
Discussion of off-label drug use: Not Applicable
Research support: Amgen Inc., Celgene Corporation, Janssen, Karyopharm Therapeutics, SkylineDx
Advisory Boards: Amgen Inc., BMS/Celgene, Janssen, Karyopharm Therapeutics, Oncopeptides, SkylineDx, Seattle Genetics

Chair European Myeloma Network
Chair Hovon Myeloma Working Group

Planning Committee
The following planning committee members have nothing to disclose:
Bio Ascend: Dru Dace, PhD; Chloe Dunnam; Kraig Steubing
UNMC: Brenda Ram, CMP, CHCP

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the University of Nebraska Medical Center and Bio Ascend. The University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity is supported by independent educational grants from GlaxoSmithKline, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Oncopeptides.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: February 1, 2021
Expires: February 1, 2022
15 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with hematologic malignancies.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Evaluate clinical trial results of frontline treatment options that are available for the treatment of patients with newly diagnosed MM
  • Review maintenance therapy strategies for patients with MM that are eligible to receive this type of therapy
  • Assess treatment approaches and sequencing of therapy for patients with relapsed and/or refractory MM
  • Optimize approaches to manage treatment-related adverse events that may occur during the treatment of patients with MM
  • Discuss clinical trials results that are investigating emerging novel agents in patients with MM

Activity Description

Major advances in the diagnosis and treatment of multiple myeloma (MM) have occurred in the past decade. In the future, studies will continue to address issues such as optimal sequencing of therapies, the incorporation of novel agents as they are approved into existing regimens, the role of MRD, optimal treatment of high-risk disease, and early interventions as a potential cure. This educational activity will provide the most up-to-date information to clinicians treating patients with MM, strategies to evaluate best practices and emerging clinical data, and expert insights on how to apply them safely and effectively to your patients.

Statement of Educational Need

Given the recent approval of various therapies for the treatment of patients with multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents, it is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage AEs. Thus, we propose to facilitate evaluation of emerging scientific and clinical data, and appropriate use of current and emerging therapies, by clinicians who treat patients with MM.

Faculty

Sagar Lonial, MD, FACP
Chief Medical Officer
Winship Cancer Institute of Emory University
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Emory University School of Medicine
Atlanta, Georgia

Pieter Sonneveld, MD, PhD
Professor of Hematology
Erasmus MC Cancer Institute/University Medical Center
Rotterdam, The Netherlands

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Conflict of Interest Policy/Disclosure Statement

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Faculty
Sagar Lonial, MD, FACP
Consulting Fees: Amgen Inc., Bristol Myers Squibb Company, Celgene Corporation, GlaxoSmithKline LLC, Janssen Oncology, Karyopharm Therapeutics, Merck & Co., Novartis

Pieter Sonneveld, MD, PhD
Employment: Hematology, Erasmus MC Cancer Institute, Rotterdam
Discussion of off-label drug use: Not Applicable
Research support: Amgen Inc., Celgene Corporation, Janssen, Karyopharm Therapeutics, SkylineDx
Advisory Boards: Amgen Inc., BMS/Celgene, Janssen, Karyopharm Therapeutics, Oncopeptides, SkylineDx, Seattle Genetics

Chair European Myeloma Network
Chair Hovon Myeloma Working Group

Planning Committee
The following planning committee members have nothing to disclose:
Bio Ascend: Dru Dace, PhD; Chloe Dunnam; Kraig Steubing
UNMC: Brenda Ram, CMP, CHCP

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the University of Nebraska Medical Center and Bio Ascend. The University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity is supported by independent educational grants from GlaxoSmithKline, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Oncopeptides.

Contact Information for Questions About the Activity

info@bioascend.com

0.50 CME
University of Nebraska Medical Center
Podium to Practice: Recent Clinical Trial Updates of Current and Emerging Approaches for the Treatment of Relapsed/Refractory Multiple Myeloma

Podium to Practice: Recent Clinical Trial Updates of Current and Emerging Approaches for the Treatment of Relapsed/Refractory Multiple Myeloma

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: January 28, 2021
Expires: January 28, 2022
30 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with multiple myeloma.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Review currently available treatment options for patients with R/R MM, and the unmet need for novel approaches, agents, and combinations in this setting
  • Evaluate the efficacy and safety of recently published clinical trial data of emerging agents and strategies being investigated in patients with R/R MM
  • Assess strategies to incorporate novel therapies into practice as they become available

Faculty

Sagar Lonial, MD, FACP
Chief Medical Officer
Winship Cancer Institute of Emory University
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Emory University School of Medicine
Atlanta, Georgia


Nina Shah, MD
Associate Professor
Department of Medicine
University of California, San Francisco
San Francisco, California


Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Conflict of Interest Policy/Disclosure Statement

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Faculty
Sagar Lonial, MD, FACP
Disclosures
Consulting Fees: Amgen Inc., Bristol Myers Squibb Company, Celgene Corporation, GlaxoSmithKline LLC, Janssen Oncology, Karyopharm Therapeutics, Merck & Co., Novartis

Nina Shah, MD
Disclosures
Consulting Fees: bluebird bio, Inc., Celgene Corporation, Janssen Oncology, Sutro Biopharma, Inc., TeneoBio
Contracted Research & Publishing: Amgen Inc., Bristol Myers Squibb, CareDx, Genentech, Inc., GlaxoSmithKline LLC, Indapta Therapeutics, Nektar Therapeutics, Precision BioSciences, Sanofi, Surface Oncology
Ownership Interest:
Indapta Therapeutics

Planning Committee
The following planning committee members have nothing to disclose:
UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Patti Bunyasaranand, MS; Dru Dace, PhD; Kraig Steubing

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the University of Nebraska Medical Center and Bio Ascend. The University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity is supported by independent educational grants from Karyopharm Therapeutics, Legend Biotech, and Sanofi Genzyme.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: January 28, 2021
Expires: January 28, 2022
30 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with multiple myeloma.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Review currently available treatment options for patients with R/R MM, and the unmet need for novel approaches, agents, and combinations in this setting
  • Evaluate the efficacy and safety of recently published clinical trial data of emerging agents and strategies being investigated in patients with R/R MM
  • Assess strategies to incorporate novel therapies into practice as they become available

Faculty

Sagar Lonial, MD, FACP
Chief Medical Officer
Winship Cancer Institute of Emory University
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Emory University School of Medicine
Atlanta, Georgia


Nina Shah, MD
Associate Professor
Department of Medicine
University of California, San Francisco
San Francisco, California


Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Conflict of Interest Policy/Disclosure Statement

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Faculty
Sagar Lonial, MD, FACP
Disclosures
Consulting Fees: Amgen Inc., Bristol Myers Squibb Company, Celgene Corporation, GlaxoSmithKline LLC, Janssen Oncology, Karyopharm Therapeutics, Merck & Co., Novartis

Nina Shah, MD
Disclosures
Consulting Fees: bluebird bio, Inc., Celgene Corporation, Janssen Oncology, Sutro Biopharma, Inc., TeneoBio
Contracted Research & Publishing: Amgen Inc., Bristol Myers Squibb, CareDx, Genentech, Inc., GlaxoSmithKline LLC, Indapta Therapeutics, Nektar Therapeutics, Precision BioSciences, Sanofi, Surface Oncology
Ownership Interest:
Indapta Therapeutics

Planning Committee
The following planning committee members have nothing to disclose:
UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Patti Bunyasaranand, MS; Dru Dace, PhD; Kraig Steubing

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the University of Nebraska Medical Center and Bio Ascend. The University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity is supported by independent educational grants from Karyopharm Therapeutics, Legend Biotech, and Sanofi Genzyme.

Contact Information for Questions About the Activity

info@bioascend.com

Pages